CALy prognostic score (CEA, ALP, Lymphocyte Count) as a predictor of survival after hepatectomy for liver-only colorectal metastases

Journal of B.U.ON.

Volumn 20, Issue 3, 2015, Pages 746-755

  Neofytou, Kyriakos ^a   Giakoustidis, Alexandras ^a   Mudan, Satvinder ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Carcinoembryonic antigen; Colorectal liver metastases; Lymphocyte count; Prognostic score; Serum alkaline phosphatase

Indexed keywords

ALKALINE PHOSPHATASE; CARCINOEMBRYONIC ANTIGEN;

ADJUVANT CHEMOTHERAPY; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALY PROGNOSTIC SCORE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; COLORECTAL LIVER METASTASIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; HUMAN; LIVER RESECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIMARY TUMOR; PROGNOSTIC ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL PREDICTION; TREATMENT RESPONSE; ADJUVANT THERAPY; ADVERSE EFFECTS; AREA UNDER THE CURVE; BLOOD; CHI SQUARE DISTRIBUTION; COLORECTAL TUMOR; FEMALE; IMMUNOLOGY; KAPLAN MEIER METHOD; LIVER NEOPLASMS; LYMPHOCYTE; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SECONDARY; TIME; TREATMENT OUTCOME;

AGED; ALKALINE PHOSPHATASE; AREA UNDER CURVE; CARCINOEMBRYONIC ANTIGEN; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84938683450     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009; 22:191-197.
2. Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist 2008; 13:51-64.
3. Fong Y, Fortner J, Sun R.L., Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309-318.
4. John SK, Robinson SM, Rehman S et al. Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: an 11-year single-centre study. Dig Surg 2013; 30:293-301.
5. Tomlinson JS, Jarnagin WR, DeMatteo RP et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007; 25:4575-4580.
6. Ayez N, Lalmahomed ZS, Van der Pool AEM et al. Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy? Ann Surg Oncol 2011:18:2757-2763.
7. Saif MW, Alexander D, Wicox CM. Serum Alkaline Phosphatase Level as a Prognostic Tool in Colorectal Cancer: A Study of 105 patients. J Appl Res 2005; 5:88-95.
8. Klompje J, Petrelli NJ, Herrera L, Mittelman A. The prognostic value of preoperative alkaline phosphatase for resection of solitary liver metastasis fromcolorectal carcinoma. Eur J Surg Oncol 1987; 13:345-347.
9. Dexiang Z, Li R, Ye W et al. Outcome of patients with colorectal liver metastasis: analysis of 1, 613 consecutive cases. Ann Surg Oncol 2012; 19:2860-2868.
10. Corthay A. Does the Immune System Naturally Protect Against Cancer? Front Immunol 2014; 5:197.
11. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
12. Friedman LS, Martin P, Munoz SJ. Liver function tests and the objective evaluation of the patient with liver disease. In: Zakim D, Boyer TD (Eds): Hepatology: a Textbook of Liver Disease. Philadelphia, Pa: WB Saunders, 1996. pp 791-833.
13. Giessen C, Fischer von Weikersthal L, Laubender RP et al. Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial. Br J Cancer 2013; 109:1428-1436.
14. Limdi JK, Hyde GM. Evaluation of abnormal liver function tests. Postgrad Med J 2003:79;307-312.
15. Sonpavde G, Pond GR, Berry WR et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol 2012; 30:607-613.
16. Li G, Gao J, Tao YL et al. Increased pretreatment levels of serum LDH and ALP as poor prognostic factors for nasopharyngeal carcinoma. Chin J Cancer 2012; 31:197-206.
17. Aminian A, Karimian F, Mirsharifi R et al. Correlation of serum alkaline phosphatase with clinicopathological characteristics of patients with oesophageal cancer. East Mediterr Health J 2011; 17:862-866.
18. Zhang K, Lai Y, Axelrod R et al. Modeling the overall survival of patients with advanced-stage non-small cell lung cancer using data of routine laboratory tests. Int J Cancer 2014: doi:10.1002/ijc.28995. [Epub ahead of print]
19. Neofytou K, Smyth EC, Giakoustidis A, Khan A.Z., Cunningham D., Mudan S. Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor. Med Oncol 2014; 31:239-248.
20. Yildirim M, Yildiz M, Duman E., Goktas S, Kaya V. Prognostic importance of the nutritional status and systemic inflammatory response in non-small cell lung cancer. J BUON 2013; 18:728-732.
21. Dirican A, Kucukzeybek Y, Somali I et al. The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma. J BUON 2013; 18:413-419.
22. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21:137-148.
23. Hoffmann TK, Dworacki G, Tsukihiro T et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002; 8:2553-2562.
24. Zhang H, Zhang M, Tao Y., Wang G, Xia B. Madecassic acid inhibits the mouse colon cancer growth by inducing apoptosis and immunomodulation. J BUON 2014; 19:372-376.
25. Duffy MJ, van Dalen A, Haglund C et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007; 43:1348-1360.
26. Selcukbiricik F, Erdamar S, Ozkurt CU et al. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer. J BUON 2013; 18:116-123.
27. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005; 23:338-351.